The association between psychopathology and placebo analgesia in patients with discogenic low back pain

Pain Medicine

Volumn 7, Issue 3, 2006, Pages 217-228

  Wasan, Ajay D ^a,d   Kaptchuk, Ted J ^b   Davar, Gudarz ^c   Jamison, Robert N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AMGEN INC   (United States)

^d PAIN MANAGEMENT CENTER OF PADUCAH   (United States)

Author keywords

Analgesic; Back pain; Opioids; Placebos; Psychiatry

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; MORPHINE; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANALGESIA; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; CROSSOVER PROCEDURE; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; EXPECTATION; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROPATHIC PAIN; NEUROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PREDICTION; PSYCHOSOMATIC DISORDER; RADICULAR PAIN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ANALGESICS, OPIOID; ANXIETY; ATTITUDE TO HEALTH; BEHAVIORAL SYMPTOMS; COMORBIDITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EMPLOYMENT; FEMALE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; INTERVERTEBRAL DISK DISPLACEMENT; LOW BACK PAIN; MALE; MORPHINE; PLACEBO EFFECT; PSYCHOPATHOLOGY; RISK ASSESSMENT; RISK FACTORS; STATISTICS; UNITED STATES;

EID: 33646452132     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00154.x     Document Type: Article

References (62)

1. Kaptchuk TJ. Powerful placebo: The dark side of the randomized controlled trial. Lancet 1998;351:1722-5.
2. Kaptchuk TJ. Intentional ignorance: A history of blind assessment and placebo controls in medicine. Bull Hist Med 1998;72:389-433.
3. DeCraen AJM, Kaptchuk TJ, Kleijnen J. Placebos and placebo effects in medicine: Historical overview. J R Soc Med 1999;92:511-5.
4. Shapiro AK, Shapiro E. Predicting placebo response. In: Shapiro AK, Shapiro E, eds. The Powerful Placebo: From Ancient Priest to Modern Physician. Baltimore, MD: Johns Hopkins University Press; 1997:217-8.
5. Fisher S. The placebo reactor: Thesis, antithesis, synthesis, and hypothesis. Dis Nerv Syst 1967;28:510-5.
6. Doongaji DR, Vahia VN, Bharucha MP. On placebos, placebo responses and placebo responders. A review of psychological, psychopharmacological and psychophysiological factors. J Postgrad Med 1978;24:147-57.
7. Joyce C. Non-specific aspects of treatment from the point of view of a clinical pharmacologists. In: Shepard M, Sartorium N, eds. Non-Specific Aspects of Treatment. Toronto: Han Hubers; 1989:57-94.
8. Honigfeld G. Non-specific factors in treatment. I. Review of placebo reactions and placebo reactors. Dis Nerv Syst 1964;25:145-56.
9. Turner JA, Deyo R, Loesser J, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994;271(20):1609-14.
10. Linton S. A review of psychological risk factors in back and neck pain. Spine 2000;25:1148-56.
11. Dworkin R, Richlin D, Handelin D, Brandt L. Predicting treatment response in depressed and non-depressed chronic pain patients. Pain 1986;24:343-53.
12. McCreary C. Empirically derived MMPI profile clusters and characteristics of low back pain patients. J Consult Clin Psychol 1985;53(4):558-60.
13. Andersson G. Epidemiological features of low back pain. Lancet 1999;354:581-5.
14. Vendrig A, Derksen J, deMey H. Utility of selected MMPI-2 scales in the outcome prediction for patients with chronic back pain. Psychol Assesss 1999;11:381-5.
15. Bair M, Robinson R, Katon W, Kroenke K. Depression and pain comorbidity: A literature review. Arch Int Med 2003;163:2433-45.
16. McWilliams L, Goodwin R, Cox B. Depression and anxiety associated with three pain conditions: Results from a nationally representative sample. Pain 2004;111:77-83.
17. Dersh J, Gatchel R, Polatin P, Mayer T. Prevalence of psychiatric disorders in patients with chronic work-related musculoskeletal pain and disability. J Occup Environ Med 2002;44(5):459-68.
18. Fishbain D. Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Med Clin North Am 1999; 83 (3): 737 -59.
19. Katon W, Egan K, Miller D. Chronic pain: Lifetime psychiatric diagnosis family history. Am J Psych 1985;142(10):1156-60.
20. Koenig T, Clark MR. Advances in comprehensive pain management. Psychiatr Clin North Am 1996;19(3):589-611.
21. Wasan AD, Davar G, Jamison RN. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain 2005;117:450-61.
22. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R, eds. Handbook of Pain Assessment. New York: Guilford Press; 2001:15-34.
23. Krause SJ, Backonja MM. The development of a neuropathic pain questionnaire. Clin J Pain 2003;19(5):315-6.
24. Fairbank JCT, Pynsent PB. The Oswestry disability index. Spine 2000;25:2940-53.
25. Geisser ME, Roth RS. Assessing depression among persons with chronic pain using the center for epidemiological studies depression scale and the beck depression inventory: A comparative analysis. Clin J Pain 1997;13:163-70.
26. Turner JA, Romano JM. Self-report screening measures for depression in chronic pain patients. J Clin Psychol 1984;40:909-13.
27. McCracken L, Zayfert C, Gross R. The pain anxiety symptoms scale: Development and validation of a scale to measure fear of pain. Pain 1992;50:67-73.
28. McCracken L, Gross R, Aikens J, Carnrike C. The assessment of anxiety and fear in persons with chronic pain: A comparison of instruments. Behav Res Ther 1996;34(11):927-33.
29. McCracken L, Gross R, Sorg P, Edmans T. Prediction of pain in patients with chronic low back pain: Effects inaccurate prediction pain-related anxiety. Behav Res Ther 1993;31(7):647-52.
30. Cox B, Borger S, Taylor S, Fuentes K, Ross L. Anxiety sensitivity and the five-factor model of personality. Behav Res Ther 1999;37:633-41.
31. Costa PT, Herbst JH, McCrae RR, Siegler IC. Personality at midlife: Stability, intrinsic maturation, and response to life events. Assessment 1992;7(4):365-78.
32. Evers A, Kraaimaat F, Van Reil P. Bijlsma J. Cognitive, behavioral and physiological reactivity to pain as a predictor of long-term pain in rheumatoid arthritis patients. Pain 2001;9:139-46.
33. Wade JB, Dougherty LM, Hart RP, Cook DB. Patterns of normal personality structure among chronic pain patients. Pain 1992;48:37-45.
34. Wade JB, Dougherty LM, Hart RP, Rafii A, Price DD. A cannonical correlation analysis of the influence of neuroticism and extraversion on chronic pain, suffering, and pain behavior. Pain 1992;51:67-73.
35. Groth-Marnat G, Fletcher A. Influence of neuroticism, catastrophizing, pain duration, and receipt of compensation on short-term response to nerve block treatment for chronic back pain. J Behav Med 2000;23(4):339-50.
36. Max MB, Laska EM. Single dose analgesic comparisons. In: Max MB, Portenoy R, Laska EM, eds. The Design of Analgesic Clinical Trials. New York: Raven Press; 1991:55-95.
37. Dellemijn P, Vanneste J. Randomised, double-blind, active-placebo controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753-8.
38. Pengel HM, Maher CG, Refshauge KM. Systematic review of conservative interventions for subacute low back pain. Clin Rehabil 2002;16(8):811-20.
39. Kaptchuk TJ, Goldman P, Stason WB. Do medical devices have enhanced placebo effects? J Clin Epidemiol 2000;53:786-92.
40. Nelson D, Novy D. Self-report differentiation of anxiety and depression in chronic pain. J Pers Assess 1997;69(2):392-407.
41. Gatchel R, Dersh J. Psychological disorders and chronic pain: Are there cause-and-effect relationships? In: Turk D, Gatchel R, eds. Psychological Approaches to Pain Management: A Practitioner's Handbook, 2nd edition. New York: Guilford Press; 2002:30-51.
42. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol 2002;1:85-91.
43. Benedetti F, Amanzio M, Baldi S, et al. The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. Pain 1998;75:313-9.
44. Turk DC, Monarch ES. Biopsychosocial perspective on chronic pain. In: Turk DC, Gatchel R, eds. Psychological Approaches to Pain Management. New York: Guilford Press; 2002:3-29.
45. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474.
46. Lieberman MD, Jarco JM, Berman S, et al. The neural correlates of placebo effects: A disruption account. Neuroimage 2004;22:447-55.
47. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia: Imaging a shared network. Science 2002;295:1737-40.
48. Wager TD, Rilling JK, Smith EE, eet al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 2004;303:1162-6.
49. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978;2:654-7.
50. Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 2005;114:3-6.
51. Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over time in irritable Bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005;115:338-47.
52. Mondloch MV, Cole DC, Frank JW. Does how you do depend on how you think you'll do? A systematic review of the evidence for a relation between patients' recovery expectations and health outcomes. CMAJ 2001;165(2):174-9.
53. Atlas SJ, Deyo RA, Keller RB, et al. The main lumbar spine study part II: 1-year outcomes of surgical and non-surgical management of sciatica. Spine 1996;21:1777-86.
54. Koes BW, Bouter LM, van der Heijden GJ. Methodological quality of randomized clinical trials on treatment efficacy on low back pain. Spine 1995;20:228-35.
55. Turner JA, Jensen M, Warms C, Cardenas D. Blinding effectiveness and association of pretreatment expectations with pain improvement in a double-blind randomized controlled trial. Pain 2002;99:91-9.
56. Price DD, Milling LS, Kirsch I, et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999;83:147-56.
57. Jensen MP, Karoly P. Motivation and expectancy factor in symptom perception: A laboratory study of the placebo effect. Psychosom Medd 199;53:144-52.
58. Fillmore M, Vogel-Sprott M. Expected effect of caffeine on motor performance predicts the type of response to placebo. Pharmacology 1992;106:209-14.
59. Hoffman GA, Harrington A, Fields HL. Pain and the placebo: What have we learned? Perspect Biol Med 2005;48(2):248-65.
60. Jamison RN, Raymond SA, Levine JG, et al. Electronic diaries for monitoring chronic pain: 1-year validation study. Pain 2001;91:277-85.
61. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients: An empirical investigation. Pain 2003;105(1-2):17-25.
62. Spitzer RL, Williams JBW, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: The Prime-MD 1000 Study. JAMA 1994;272(22):1749-56.